Previous 10 | Next 10 |
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021, at 2:20 p.m. ET. Th...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q2 2021 Earnings Call Aug 03, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q2 2021 Earnings Call Transcript ...
Start Time: 16:30 End Time: 17:33 Global Blood Therapeutics, Inc. (GBT) Q2 2021 Earnings Conference Call August 03, 2021, 16:30 PM ET Company Participants Ted Love - President and CEO Jeff Farrow - CFO David Johnson - Chief Commercial Officer Kim Smith-Whitley - EVP and Head of R&D Steven...
Global Blood Therapeutics (NASDAQ:GBT): Q2 GAAP EPS of -$1.12 beats by $0.07. Revenue of $47.56M (+51.0% Y/Y) beats by $3.67M. Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe. Advanced pipeline with initiation ...
Achieved Oxbryta ® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in Europe Advanced pipeline with initiation of two i...
AFG, AIZ, AKAM, AMGN, APAM, ATVI, AYX, BKH, BLKB, BNFT, CAR, CDLX, COUR, CW, CZR, DCPH, DEI, DENN, DK, DVA, DVN, ET, EVTC, FICO, FMC, FNF, FRG, GBT, GDOT, H, HPP, HST, ICFI, ICHR, INFN, INSP, IOSP, JAZZ, KAI, KAR, KFRC, KTOS, KWR, LPSN, LSCC, LSI, LYFT, LYV, MANT, MGRC, MRCY, MTCH, MYGN, NBIX...
Global Blood Therapeutics Inc. (NASDAQ:GBT) traded at a new 52-week low today of $27.11. This new low was reached on below average trading volume as 153,000 shares traded hands, while the average 30-day volume is approximately 1.5 million shares. Global Blood Therapeutics Inc. share pric...
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2021 financial results on Tuesday, August 3, 2021, after U.S. financial markets close. Management will host a ...
Global Blood Therapeutics Inc. (NASDAQ:GBT) traded today at a new 52-week low of $28.88. This new low was reached on below average trading volume as 153,000 shares traded hands, while the average 30-day volume is approximately 1.5 million shares. Global Blood Therapeutics Inc operates in...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...